

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/857,695	06/08/2001	Yoshinobu Kiso	46/219	1040	
20736 7	590 03/23/2004		EXAMINER		
MANELLI DENISON & SELTER			KHARE, DEVESH		
2000 M STREET NW SUITE 700 WASHINGTON, DC 20036-3307			ART UNIT	PAPER NUMBER	
	,		1623		
			DATE MAILED: 03/23/2004	DATE MAILED: 03/23/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

•	Application No.					
		Applicant(s)				
Office Action Summan	09/857,695	KISO ET AL.				
Office Action Summary	Examiner	Art Unit				
71 11 11 11 11 11 11 11 11 11 11 11 11 1	Devesh Khare	1623				
The MAILING DATE of this communication a Period for Reply	appears on the cover sheet wit	th the correspondence address				
A SHORTENED STATUTORY PERIOD FOR REF THE MAILING DATE OF THIS COMMUNICATION - Extensions of time may be available under the provisions of 37 CFR after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a r - If NO period for reply is specified above, the maximum statutory perions - Failure to reply within the set or extended period for reply will, by state Any reply received by the Office later than three months after the material patent term adjustment. See 37 CFR 1.704(b).	N. 1.136(a). In no event, however, may a re reply within the statutory minimum of thirty od will apply and will expire SIX (6) MONI lute. cause the application to become ANI	eply be timely filed (30) days will be considered timely. THS from the mailing date of this communication.				
Status						
1) Responsive to communication(s) filed on <u>01</u>	October 2003					
3) Since this application is in condition for allow		ers, prosecution as to the merits is				
closed in accordance with the practice unde	r <i>Ex parte</i> Quayle, 1935 C.D.	11, 453 O.G. 213.				
Disposition of Claims						
4) Claim(s) is/are pending in the applica	tion					
4a) Of the above claim(s) is/are withdi						
5) Claim(s) is/are allowed.	am nom obnolaciation.					
6)☐ Claim(s) is/are rejected.	·					
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1,4,5,8,9,12 and 19-27</u> are subject t	to restriction and/or election r	equirement.				
Application Papers						
9)☐ The specification is objected to by the Examir	ner					
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.						
Applicant may not request that any objection to th	e drawing(s) be held in abevance	e See 37 CFR 1 85(a)				
Replacement drawing sheet(s) including the corre						
11) The oath or declaration is objected to by the E	Examiner. Note the attached (Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreig a) All b) Some * c) None of: 1. Certified copies of the priority documer 2. Certified copies of the priority documer 3. Copies of the certified copies of the priority application from the International Burea * See the attached detailed Office action for a list	nts have been received. Its have been received in Apportly documents have been read (PCT Rule 17.2(a)).	olication No eceived in this National Stage				
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date	Paper No(s)/N	nmary (PTO-413) Mail Date rmal Patent Application (PTO-152)				

Application/Control Number: 09/857,695

Art Unit: 1623

1

Applicant's Amendment and remarks filed on 10/01/03 are acknowledged.

Claims 1,5 and 9 have been amended. Claims 2,3,6,710,11 and 13-18 have been cancelled. New claims 19-27 have been added.

Claims 1,4,5,8,9,12 and 19-27 are currently pending in this application.

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

- I. Claims 1,4,5,8,9, and 12, drawn to toward a composition (blood ammonia lowering agent), containing xylobiose as an active agent, classified in classes 536 and 424, subclass various.
- II. Claims 19-27, drawn to a method of lowering blood ammonia in a patient with hyperammonemia or hepatic encephalopathy by administering xylobiose, classified in class 514, subclass various.

The inventions are distinct, each from the other because of the following reasons:

Groups I to II are related as product and process of making. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the process for using the product can be

Application/Control Number: 09/857,695

Art Unit: 1623

practiced with another materially different product i.e. a method of lowering blood ammonia in a patient can be practiced with another materially different product such as lactulose, raffinose or isomaltooligosaccharide, see EP 382,355 (Mitsuhashi et al.). Although the inventions are classified in the same class and sub-class, searching the two groups of inventions constitutes a burdensome search, as a thorough search comprises a search or foreign patents and non-patent literature as well as the appropriate U.S. patent classifications. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their divergent subject matter, restriction for examination purposes as indicated is proper. It is noted that examination of the two independent and distinct inventions would indeed impose an undue burden upon the examiner in charge of this application.

Election of Species

In addition to an election of one of the above Groups, restriction is further required under 35 U.S.C. 121 to elect a single disclosed species if **Group II** is elected: Election of one of the following species is required in the Method of lowering blood ammonia:

- 1. Treating patient with hyperaamonemia.
- 2. Treating patient with hepatic encephalopathy.

Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement is traversed (37 CFR 1.143). If applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims, which depend from or

Art Unit: 1623

otherwise include all the limitations of the allowable product claim will be rejoined.

(MPEP § 821.04)

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a diligently-filed petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(h).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. Process claims that depend from or otherwise include all the limitations of the patentable product will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of In re Ochiai, In re Brouwer and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Examiner should be directed to Devesh Khare whose telephone number is (571) 272-0653.

The examiner can normally be reached on Monday to Friday from 8:00 to 4:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James O. Wilson, Supervisory Patent Examiner, Art Unit 1623 can be reached at 571-272-0661. The official fax phone numbers for the organization where this application or proceeding is assigned is (703) 308-4556 or 308-4242.

Art Unit: 1623

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

Devesh Khare, Ph.D., JD(3Y). Art Unit 1623 March 18, 2004

/\JAMES O. WILSON

SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600